FCH
RNAC icon

Freestone Capital Holdings’s Cartesian Therapeutics RNAC Stock Holding History

Freestone Capital Holdings’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,921
Closed -$265K – 591
2025
Q3 		$265K Hold
25,921
– – 0.01% 453
2025
Q2 		$269K Hold
25,921
– – 0.01% 384
2025
Q1 		$342K Hold
25,921
– – 0.01% 336
2024
Q4 		$464K Hold
25,921
– – 0.02% 296
2024
Q3 		$418K Buy
25,921
+17,921
+224% +$280K 0.01% 320
2024
Q2 		$216K Buy
+8,000
New +$191K 0.01% 428

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Freestone Capital Holdings's RNAC Position: Q4 2025 in Review

Freestone Capital Holdings sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 25,921 shares — an estimated $265K sold.

Freestone Capital Holdings first reported a position in RNAC in Q2 2024 and held it in 6 quarters. The position peaked at $464K in Q4 2024. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • Freestone Capital Holdings reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Freestone Capital Holdings sold 25,921 Cartesian Therapeutics shares in Q4 2025, an estimated $265K.
  • Freestone Capital Holdings first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 6 quarters.
  • Freestone Capital Holdings's Cartesian Therapeutics position peaked at $464K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Freestone Capital Holdings's 13F filing for Q4 2025, filed 23 Jan 2026.